Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis
Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Rena...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2021-06, Vol.13 (9), p.783-793 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 793 |
|---|---|
| container_issue | 9 |
| container_start_page | 783 |
| container_title | Immunotherapy |
| container_volume | 13 |
| creator | Rizzo, Alessandro Mollica, Veronica Santoni, Matteo Rosellini, Matteo Marchetti, Andrea Ricci, Angela Dalia Grilli, Giada Greco, Alba Montironi, Rodolfo Ardizzoni, Andrea Massari, Francesco |
| description | Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups.
All the relevant randomized clinical trials were retrieved through Cochrane library, PubMed/Med and EMBASE; three Phase III randomized clinical trials were included.
ICI–TKI combinations significantly decreased the risk of death in IMDC poor- and intermediate-risk patients. Conversely, a nonstatistically significant benefit was observed in favorable-risk patients.
Our results suggest that IMDC poor-risk patients benefit most from ICI–TKI combinations, while a proportion of metastatic renal cell carcinoma patients could respond to targeted agent monotherapy. |
| doi_str_mv | 10.2217/imt-2021-0005 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_imt_2021_0005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33906376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-2d322ec40788b14c5fc415b17eb02f1a9282ca28d89d9df7d3e3fcd6106936f73</originalsourceid><addsrcrecordid>eNp1kcuO1TAMhiMEYi6wZIvyAmVy6WladuhwG2kQG5DYVanrzITTJlWcIp234S3Y82SkHBixYeOL_Nmy_TP2TIoXSklz5edcKaFkJYTYPWDn0uxEZeq6fXgf6y9n7ILoqxBNbZr6MTvTuhONNs05-7GP82KTzf4bcnQOYYsCEvHouPOJcjX5gNzP81oc3CEcluhD5j7c-cHnmIgv00o8H1OkDT34YAn_rVuAmEYfbnmO_PrD6_3P78nTgd-muC5USD5jtpTLGsATBjtxwKkYm8CHONuX3P5GKltqR_L0hD1ydiJ8-sdfss9v33zav69uPr673r-6qUDXunxm1Eoh1MK07SBr2Dmo5W6QBgehnLSdahVY1Y5tN3ajM6NG7WBspGg63TijL1l1mgvlOEro-iX52aZjL0W_CdAXAfpNgH4ToPDPT_yyDjOO9_TfjxegOwFuzWtCAo8BsD9lpcOXg_E_w38BYDGbiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Rizzo, Alessandro ; Mollica, Veronica ; Santoni, Matteo ; Rosellini, Matteo ; Marchetti, Andrea ; Ricci, Angela Dalia ; Grilli, Giada ; Greco, Alba ; Montironi, Rodolfo ; Ardizzoni, Andrea ; Massari, Francesco</creator><creatorcontrib>Rizzo, Alessandro ; Mollica, Veronica ; Santoni, Matteo ; Rosellini, Matteo ; Marchetti, Andrea ; Ricci, Angela Dalia ; Grilli, Giada ; Greco, Alba ; Montironi, Rodolfo ; Ardizzoni, Andrea ; Massari, Francesco</creatorcontrib><description>Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups.
All the relevant randomized clinical trials were retrieved through Cochrane library, PubMed/Med and EMBASE; three Phase III randomized clinical trials were included.
ICI–TKI combinations significantly decreased the risk of death in IMDC poor- and intermediate-risk patients. Conversely, a nonstatistically significant benefit was observed in favorable-risk patients.
Our results suggest that IMDC poor-risk patients benefit most from ICI–TKI combinations, while a proportion of metastatic renal cell carcinoma patients could respond to targeted agent monotherapy.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2021-0005</identifier><identifier>PMID: 33906376</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; axitinib ; Carcinoma, Renal Cell - drug therapy ; Humans ; immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - administration & dosage ; immunotherapy ; Kidney Neoplasms - drug therapy ; Molecular Targeted Therapy - methods ; Protein Kinase Inhibitors - administration & dosage ; renal cell carcinoma ; tyrosine kinase inhibitors</subject><ispartof>Immunotherapy, 2021-06, Vol.13 (9), p.783-793</ispartof><rights>2021 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-2d322ec40788b14c5fc415b17eb02f1a9282ca28d89d9df7d3e3fcd6106936f73</citedby><cites>FETCH-LOGICAL-c343t-2d322ec40788b14c5fc415b17eb02f1a9282ca28d89d9df7d3e3fcd6106936f73</cites><orcidid>0000-0002-5257-8678 ; 0000-0001-6476-6871 ; 0000-0002-5169-3631</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33906376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rizzo, Alessandro</creatorcontrib><creatorcontrib>Mollica, Veronica</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Rosellini, Matteo</creatorcontrib><creatorcontrib>Marchetti, Andrea</creatorcontrib><creatorcontrib>Ricci, Angela Dalia</creatorcontrib><creatorcontrib>Grilli, Giada</creatorcontrib><creatorcontrib>Greco, Alba</creatorcontrib><creatorcontrib>Montironi, Rodolfo</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><title>Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups.
All the relevant randomized clinical trials were retrieved through Cochrane library, PubMed/Med and EMBASE; three Phase III randomized clinical trials were included.
ICI–TKI combinations significantly decreased the risk of death in IMDC poor- and intermediate-risk patients. Conversely, a nonstatistically significant benefit was observed in favorable-risk patients.
Our results suggest that IMDC poor-risk patients benefit most from ICI–TKI combinations, while a proportion of metastatic renal cell carcinoma patients could respond to targeted agent monotherapy.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>axitinib</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Humans</subject><subject>immune checkpoint inhibitors</subject><subject>Immune Checkpoint Inhibitors - administration & dosage</subject><subject>immunotherapy</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>renal cell carcinoma</subject><subject>tyrosine kinase inhibitors</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcuO1TAMhiMEYi6wZIvyAmVy6WladuhwG2kQG5DYVanrzITTJlWcIp234S3Y82SkHBixYeOL_Nmy_TP2TIoXSklz5edcKaFkJYTYPWDn0uxEZeq6fXgf6y9n7ILoqxBNbZr6MTvTuhONNs05-7GP82KTzf4bcnQOYYsCEvHouPOJcjX5gNzP81oc3CEcluhD5j7c-cHnmIgv00o8H1OkDT34YAn_rVuAmEYfbnmO_PrD6_3P78nTgd-muC5USD5jtpTLGsATBjtxwKkYm8CHONuX3P5GKltqR_L0hD1ydiJ8-sdfss9v33zav69uPr673r-6qUDXunxm1Eoh1MK07SBr2Dmo5W6QBgehnLSdahVY1Y5tN3ajM6NG7WBspGg63TijL1l1mgvlOEro-iX52aZjL0W_CdAXAfpNgH4ToPDPT_yyDjOO9_TfjxegOwFuzWtCAo8BsD9lpcOXg_E_w38BYDGbiw</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Rizzo, Alessandro</creator><creator>Mollica, Veronica</creator><creator>Santoni, Matteo</creator><creator>Rosellini, Matteo</creator><creator>Marchetti, Andrea</creator><creator>Ricci, Angela Dalia</creator><creator>Grilli, Giada</creator><creator>Greco, Alba</creator><creator>Montironi, Rodolfo</creator><creator>Ardizzoni, Andrea</creator><creator>Massari, Francesco</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-5257-8678</orcidid><orcidid>https://orcid.org/0000-0001-6476-6871</orcidid><orcidid>https://orcid.org/0000-0002-5169-3631</orcidid></search><sort><creationdate>20210601</creationdate><title>Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis</title><author>Rizzo, Alessandro ; Mollica, Veronica ; Santoni, Matteo ; Rosellini, Matteo ; Marchetti, Andrea ; Ricci, Angela Dalia ; Grilli, Giada ; Greco, Alba ; Montironi, Rodolfo ; Ardizzoni, Andrea ; Massari, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-2d322ec40788b14c5fc415b17eb02f1a9282ca28d89d9df7d3e3fcd6106936f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>axitinib</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Humans</topic><topic>immune checkpoint inhibitors</topic><topic>Immune Checkpoint Inhibitors - administration & dosage</topic><topic>immunotherapy</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>renal cell carcinoma</topic><topic>tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rizzo, Alessandro</creatorcontrib><creatorcontrib>Mollica, Veronica</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Rosellini, Matteo</creatorcontrib><creatorcontrib>Marchetti, Andrea</creatorcontrib><creatorcontrib>Ricci, Angela Dalia</creatorcontrib><creatorcontrib>Grilli, Giada</creatorcontrib><creatorcontrib>Greco, Alba</creatorcontrib><creatorcontrib>Montironi, Rodolfo</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rizzo, Alessandro</au><au>Mollica, Veronica</au><au>Santoni, Matteo</au><au>Rosellini, Matteo</au><au>Marchetti, Andrea</au><au>Ricci, Angela Dalia</au><au>Grilli, Giada</au><au>Greco, Alba</au><au>Montironi, Rodolfo</au><au>Ardizzoni, Andrea</au><au>Massari, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>13</volume><issue>9</issue><spage>783</spage><epage>793</epage><pages>783-793</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups.
All the relevant randomized clinical trials were retrieved through Cochrane library, PubMed/Med and EMBASE; three Phase III randomized clinical trials were included.
ICI–TKI combinations significantly decreased the risk of death in IMDC poor- and intermediate-risk patients. Conversely, a nonstatistically significant benefit was observed in favorable-risk patients.
Our results suggest that IMDC poor-risk patients benefit most from ICI–TKI combinations, while a proportion of metastatic renal cell carcinoma patients could respond to targeted agent monotherapy.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>33906376</pmid><doi>10.2217/imt-2021-0005</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5257-8678</orcidid><orcidid>https://orcid.org/0000-0001-6476-6871</orcidid><orcidid>https://orcid.org/0000-0002-5169-3631</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2021-06, Vol.13 (9), p.783-793 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_imt_2021_0005 |
| source | MEDLINE; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use axitinib Carcinoma, Renal Cell - drug therapy Humans immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage immunotherapy Kidney Neoplasms - drug therapy Molecular Targeted Therapy - methods Protein Kinase Inhibitors - administration & dosage renal cell carcinoma tyrosine kinase inhibitors |
| title | Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A33%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20effectiveness%20of%20first-line%20immune%20checkpoint%20inhibitors%20plus%20tyrosine%20kinase%20inhibitors%20according%20to%20IMDC%C2%A0risk%20groups%20in%20metastatic%20renal%20cell%20carcinoma:%20a%20meta-analysis&rft.jtitle=Immunotherapy&rft.au=Rizzo,%20Alessandro&rft.date=2021-06-01&rft.volume=13&rft.issue=9&rft.spage=783&rft.epage=793&rft.pages=783-793&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2021-0005&rft_dat=%3Cpubmed_cross%3E33906376%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33906376&rfr_iscdi=true |